P3 Health Partners (PIII) Q1 2026 earnings review
A Staggering Turnaround on Paper, But Cash Conversion Lags
After a disastrous 2025 marked by severe prior-period adjustments and plummeting margins, P3 Health Partners delivered exactly what it promised: a Reversing trend to profitability. Q1 2026 Adjusted EBITDA swung to a positive $25.8 million, obliterating the deep losses of the prior four quarters. This was driven by a ruthless 10% reduction in at-risk membership, culling unprofitable contracts to drive a 14% surge in per-member revenue. Consequently, management raised its FY26 Adjusted EBITDA midpoint by a massive 300% to $40 million. However, investors must look beneath the surface: Operating Cash Flow remains heavily negative at -$27.5 million as health plan receivables spiked. The company is now profitable on the income statement, but cash burn remains a critical risk.
🐂 Bull Case
The company's strategy to shed bad contracts and renegotiate terms was wildly successful. Even excluding favorable prior-year development, normalized medical margin was $56.1 million, proving the underlying Care Enablement Model works when paired with rational pricing.
Management's confidence is backed by numbers. Raising the FY26 Adjusted EBITDA midpoint from $10M to $40M just one quarter into the year signals that the $125M in expected contract/revenue improvements are firmly locked in.
🐻 Bear Case
Despite reporting $3.0M in Net Income, Operating Cash Flow was -$27.5M. With only $26.1M in total cash and restricted cash remaining, P3 is walking a tightrope and may need to raise capital if receivables are not collected immediately.
At-risk membership continues its Decelerating trend, dropping to 106,000. Management had to lower its FY26 membership guidance range, suggesting the 'floor' for the network rationalization process is lower than previously anticipated.
⚖️ Verdict: 🟢
Bullish. The sheer magnitude of the margin turnaround outweighs the shrinking membership. However, the disconnect between paper profits and actual cash generation must be monitored closely—profitability means little if the company runs out of cash before health plans pay their bills.
Key Themes
Network Rationalization Drives Surging Unit Economics
The decision to intentionally shrink the network is paying massive dividends. At-risk membership dropped 10% YoY, but Total Revenue actually grew 4% to $386M. This Reversing dynamic resulted in a 14% spike in per-member revenue. By focusing on highly aligned, higher-performing Tier 1 providers and cutting loose the dead weight, P3 has fundamentally reset its unit economics.
Profit Quality and the Cash Flow Disconnect
While Net Income turned positive for the first time in over a year ($3.0M), Operating Cash Flow remained deep in the red at -$27.5M. The culprit is a massive spike in 'Health plan receivable', which drained $32.4M of cash. P3 is recognizing revenue that health plans have not yet paid. If this represents disputed claims or delayed settlements, the paper profitability will not save the balance sheet.
Favorable Prior Year Development
Throughout 2025, P3 was hammered by negative prior-period adjustments (PPAs) that destroyed margins. In Q1 2026, this trend flipped. The reported $73.7M Medical Margin included favorable PYD and payer settlements. Even stripping these out, the normalized Medical Margin of $56.1M is a massive improvement over the $17.2M reported in Q1 2025, but the favorable tailwind indicates the company's accrual conservatism has finally aligned with reality.
Debt Burden Expanding to Cover Cash Burn
To fund the ongoing cash burn, P3 increased its Long-term debt, drawing an additional $27M net in the quarter. Total debt (short and long term) now exceeds $310M. Interest expense practically doubled YoY to $16.8M for the quarter. The company is in a race to translate its new Adjusted EBITDA into hard cash before debt service costs consume the operating improvements.
Other KPIs
Decelerating. Medical claims dropped roughly 10% YoY from $372.0M in Q1 2025. This perfectly mirrors the 10% drop in at-risk membership, indicating that the company successfully managed medical cost inflation to a flat per-member basis while aggressively growing per-member revenue.
Decelerating. This liability dropped significantly from $69.8M at the end of 2025. The cash outflow used to pay down these settlements contributed to the quarter's negative operating cash flow, but successfully cleans up the balance sheet from 2025's poor contract performance.
Guidance
Accelerating. This is a massive upward revision from the previous midpoint of $10M (range -$20M to $40M). It signals that the 2026 turnaround, highly dependent on the Q1 renegotiation cycle, has structurally succeeded.
Accelerating. P3 raised this from prior expectations of $160M - $200M. The new midpoint of $210M implies sustained execution of the margin expansion seen in Q1, translating to an expected $149 - $180 PMPM.
Decelerating. Management previously guided for 107,000 to 117,000 members. The reduction indicates that the company is willing to sacrifice even more top-line scale to protect the bottom line, or that provider attrition was slightly higher than anticipated.
Key Questions
Receivables vs Cash Collection
With Health Plan Receivables jumping by $32 million in a single quarter and driving deeply negative Operating Cash Flow, what is the exact mechanism and timeline for collecting these funds, and are any of these revenues currently in dispute?
PYD Breakdown
You noted favorable prior year development and settlements aided the $73.7M Medical Margin. What is the specific dollar amount of the PYD, and does it reverse any of the specific, highly scrutinized negative adjustments recorded in Q2 and Q3 of 2025?
Membership Floor
With the downward revision to FY26 At-Risk Membership guidance, have we reached the absolute floor of the network and payer rationalization process, or should we expect further strategic divestitures in 2026?
Liquidity Runway
Given the $26 million cash balance and negative operating cash flow, what is the contingency plan if debt markets tighten? Do you expect operating cash flow to turn positive in Q2?